



Floseal
Haemostatic Matrix

FROM THE START
FOR BETTER OUTCOMES

HAVE **FLOSEAL** READY.



Baxter

In a prospective, randomised, controlled trial, the use of Floseal alone (n=110) to treat intraoperative bleeding during cardiac surgeries was found to result in better clinical and resource utilisation outcomes relative to Surgicel Nu-Knit and Gelfoam (n=104)¹.

53%

**FEWER
TRANSFUSIONS OF
BLOOD PRODUCTS¹**

67%

**LOWER REVISION
RATE FOR BLEEDING¹**

Using **FLOSEAL alone** in cardiac surgery results in 53% fewer transfusions of blood products and 67% lower revision rate for bleeding, when compared to using Surgicel Nu-Knit and/or Gelfoam.

*Revisions for bleeding for Floseal n=5 (4.5%) vs Surgicel Nu-Knit and/or Gelfoam n=14 (13.5%), p<0.04

*Transfusion of blood products for Floseal n=61 (29.2%) vs Surgicel Nu-Knit and/or Gelfoam n=97 (47.1%), p<0.001



24 MINUTES¹
REDUCED OPERATIVE TIME*

* between decannulation and closure of the sternum

Surgical teams are able to perform cardiac surgery 24 minutes (p<0.001) faster on average using **FLOSEAL alone** when compared to Surgicel Nu-Knit and/or Gelfoam¹.

\$
(AUD)

**FLOSEAL CAN SAVE
UP TO \$12,413**
PER CARDIAC PROCEDURE^{1,2}

Using **FLOSEAL alone** in cardiac surgery results in lower transfusions, surgical revisions, and surgical time, saving up to AUD \$12,413 per procedure when compared to using Surgicel Nu-Knit and/or Gelfoam^{1,2}.

**Be prepared at the start of surgery. From the routine to the unexpected.
Have FLOSEAL Ready.**

For questions or ordering information, please contact your Baxter representative.

FLOSEAL Haemostatic Matrix Indication³

FLOSEAL Matrix³ is indicated in surgical procedures (other than in ophthalmic) as an adjunct to haemostasis when control of bleeding, ranging from oozing to spurting, by ligature or conventional procedures is ineffective or impractical.

Refer to Full Instructions for Use before prescribing. Full Instructions For Use are available from Baxter Medical Information 1300 302 409 (Australia) or 0800 556 682 (New Zealand) or email onecall@baxter.com.

1. Giuseppe Nasso, Felice Piancone, Raffaele Bonifazi et. al. Prospective, Randomized Clinical Trial of the FloSeal Matrix Sealant in Cardiac Surgery DOI: 10.1016/j.athoracsur.2009.07.014

2. Psarros G, McElduff P, Hardy K., COST CONSEQUENCE ANALYSIS OF TWO DIFFERENT ACTIVE FLOWABLE HAEMOSTATIC MATRICES IN AN AUSTRALIAN SETTING, September 2018. DOI: 10.1016/j.jval.2018.07.230

3. Floseal Haemostatic Matrix Instructions for Use. Rev. Date 2015-05-22

Australia
Baxter Healthcare Pty Ltd
1 Baxter Drive, Old Toongabbie,
NSW 2146, Australia
Ph: +61 1800 229 837
www.baxterhealthcare.com.au

New Zealand
Baxter Healthcare Ltd
33 Vestey Drive, Mt Wellington,
Auckland, New Zealand
Ph: +64 [0] 800 229 837
www.baxter.co.nz

Baxter